Possible influence of prolactin secretion on the survival time in untreated metastatic triple negative breast cancer patients

Abstract

Even though there are controversial results, it has been shown that PRL may act as tumor growth factor in the common breast cancer, whereas it remains to be established the role of PRL in the triple negative breast cancer (TNBC). This preliminary study has been performed in an attempt to evaluate PRL blood levels in a group of metastatic TNBC patients, for whom no other effective therapy was available. The study included 21 consecutive patients. PRL serum levels were measured by the IRMA method. Abnormally high PRL levels were seen in 11/21 (52%) patients. Mean lymphocyte count was significantly higher in patients with normal than in those with high PRL values. The percentage of 1-year survival occurring in normo prolactinemic patients was significantly higher than that achieved in the hyperprolactinemic ones (6/10 vs 2/11, P<0.05). The results of this study would suggest that the evidence of abnormally high blood levels of PRL is associated with a lower survival time in metastatic TNBC patients treated by the only palliative care.

Keywords: breast cancer, hyperprolactinemia, prolactin, triple negative breast cancer

Introduction

It is known since more than 30 years that the pituitary hormone prolactin (PRL) may stimulate breast cancer development and growth in experimental conditions. In contrast, despite the fact that PRL is one of the first identified endogenous factor involved in the stimulation of mammary tumors, as well as despite the evidence that cancer-related hyper-prolactinemia has been proven to be associated with a poor prognosis, very few clinical studies have been performed in an attempt to investigate the possible prognostic significance of PRL secretion in human breast cancer and the influence of the inhibition of PRL secretion on the clinical course of breast tumors, and in particular no clinical study of PRL secretion in breast cancer has been carried out during the last 20 years. This evidence would be the consequence of the fact that almost all oncological studies performed in the last 20 years have been substantially limited to the investigation of the only biological and genetic characteristics of the different breast cancer sub-types rather than to concomitantly evaluate the biological response of patients, including their endocrinological and immune status, even though preliminary clinical studies had already suggested that the association of anti-prolactinemic agents, such as bromocriptine and cabergoline, may improve the efficacy of the commonly used oncological therapies for the metastatic breast cancer.

In any case, it has to be remarked that the relation between PRL and human breast cancer is very complex, and controversial results have been reported in the literature, particularly in the biologically more aggressive triple negative breast cancer (TNBC), which represents about 20% of human mammary tumors, since either a stimulatory or an inhibitory effect has been reported. TNBC is defined as a breast tumor lacking the expression of ER, PgR and epidermal growth factor-2 (HER2). Particularly controversial are the results concerning the physiopathological and prognostic significance of the expression of PRL-receptor (PRL-R) in breast cancer. In mammary carcinomas other than TNBC, PRL-R expression is generally associated with a less malignancy and a better prognosis, whereas its significance in TNBC has still to be better defined, even though preliminary results would suggest that the evidence of PRL-R expression would prevent the onset of TNBC and would be associated with a more favourable prognosis. In any case, the detection of PRL-R expression could allow a novel sub-classifier of TNBC, consisting of TNBC with positivity for PRL-R expression and TNBC without PRL-R expression, which could constitute quadruple negative breast cancer (QNBC) sub-type, being negative also for PRL-R. Preliminary studies would show that PRL-R expression is down regulated in TNBC. PRL antagonists have been proven to inhibit breast cancer cell proliferation by inducing the apoptosis, whereas no efficacy has been referred with PRL-R antagonists. Because of the controversial results about the effects of PRL on TNBC growth in vitro and in experimental conditions, further informations may be achieved by investigating PRL secretion in TNBC patients, by correlating its behavior with the clinical course of disease. This preliminary study was performed to evaluate PRL blood levels in untreated metastatic TNBC patients, for whom no other standard anticancer therapies were available, then suitable for the only palliative therapy, in an attempt to identify possible differences in the survival time in relation to PRL blood concentrations.

Patients and methods

The study included 21 consecutive untreated metastatic TNBC patients (median age 55 years, range 34-72). Eligibility criteria were, as follows: histologically proven TNBC, metastatic measurable disease, no double tumor, no availability of further standard anticancer therapy. According to the blood levels of PRL, patients were sub-divided into groups, consisting of normo-prolactinemic and hyper-prolactinemic patients. Patients under chronic therapy with anti-dopaminergic agents, corticosteroids, or opioids were not included in the study, because of the potential stimulatory effect of these agents on PRL secretion. The
supportive care was the same in all patients, and it consisted of non-
steroid anti-inflammatory agents for pain, corticosteroids and opioids
only in the presence of dyspnoea and acute pain, respectively. The
clinical characteristics of the two groups of patients are reported in
Table 1. For PRL detection, venous blood samples were drawn at 8.00
A.M. after an overnight fast. To exclude possible transient phase of
hyper-prolactinemia, venous blood sampling was repeated after 10
days. Serum levels of PRL were measured in duplicate by using an
immunoradiometric method (IRMA) and commercially available kits.
PRL levels were considered to be within the normal range when they
were less than 23 ng/ml (95% confidence limits). Data were reported
as mean +/- SE, and statistically analyzed by the chi-square test and
the Student’s t test, as appropriate.

Results
As shown in Table 1, the two groups of patients with normal
or abnormally high PRL levels were well comparable for the main
prognostic variables, including dominant metastasis sites, age and
performance status (PS). Abnormally high levels of PRL were found in
11/21 (52%) patients, whereas the remaining 10 patients showed
normal PRL concentrations. By repeating blood sampling, patients with
normal or high PRL levels still persisted to be normoprolactinemic or
hyperprolactinemic patients. After a minimum follow-up of 1 year, the
percentage of survival observed in normoprolactinemic patients was
significantly higher than that found in the hyper-prolactinemic group
(6/10(60%) vs 2/11(18%), P<0.05). From an immune point of view,
hyperprolactinemic patients showed a significantly lower lymphocyte
mean count that the normoprolactinemic ones(1.946±128 vs 921±287/
mm³, P<0.05), while no difference occurred in monocyte mean count
(630±36 vs 557±72/mm³). Then, lymphocyte-to-monocyte ratio
(LMR) observed in normoprolactinemic patients was significantly
higher than that found in the group of the hyperprolactinemic patients
(3.2±0.2 vs 1.8±0.3, P<0.025).

Table 1 Clinical characteristics of metastatic TNBC patients in relation to
their PRL values

| PRL values | Normal PRL values | High |
|------------|------------------|------|
| N          | 10               | 11   |
| Median age (years) | 56 (43-72) | 54 (34-70) |
| Median Performance status (Karnofsky’s score) | 100 (80-100) | 100 (80-100) |
| Dominant metastasis sites | | |
| - Nodes | 2 | 2 |
| - Bone | 1 | 1 |
| - Lung | 2 | 3 |
| - Liver | 3 | 3 |
| - Brain | 2 | 2 |

Discussion
The results of this preliminary study would suggest that the
evidence of abnormally high PRL blood levels is associated with
a reduced survival in untreated metastatic TNBC. Since the only
palliative therapy was given to patients and no other potentially
effective anticancer treatment was made, it is probable that the
same PRL levels may influence the clinical course of the disease.
This finding is not surprising, since most experimental studies have
shown a stimulatory role of PRL on breast cancer cell proliferation.5,6
In addition, because of the evidence of significantly lower values
of both lymphocyte count and LMR, which has been shown to
predict a poor prognosis,10-12 the more negative prognosis observed
in hyperprolactinemic metastatic TNBC patients could depend at
least in part on a more severe immunosuppressive status induced by
PRL itself, which has been proven to exert immunomodulating effects.1,3
Obviously, these preliminary results are not sufficient to
justify the use of anti-prolactinemic agents in metastatic TNBC,
because of the controversial results reported in the literature,5,9 since
PRL has been shown to either promote, or counteract the generation
and growth of TNBC. In particular, there is an apparent opposite
prognostic significance between PRL-R expression and PRL blood
levels in TNBC patients, since while PRL-R expression would predict
a better prognosis, metastatic TNBC-related hyperprolactinemia
would be associated with a poor prognosis and a lower survival. This
controversial result could be only apparent, since PRL-R expression
may simply reflect a major biological differentiation on the basis of
the fact that normal breast cancer cells normally express PRL-R,14
whereas PRL itself could directly stimulate cancer cell proliferation.1
Moreover, other endocrine and neuroendocrine receptors could be
involved in determining the prognosis of the TNBC. In particular, the
expression of the receptor for the antitumor pineal hormone melatonin
(MLT),15 as well as that for cannabinoid agonists,16 have been proven
to be associated with a more favourable prognosis in the TNBC. In
any case, if the negative prognostic significance of metastatic TNBC-
related hyperprolactinemia will be confirmed in a greater number of
patients, because of their low cost and lack of important toxicity, the
anti-prolactinemic agents, such as bromocriptine and cabergoline,
could be investigated in the treatment of metastatic TNBC patients,
for whom no other standard effective therapy is available, at least in
patients with abnormally high blood levels of PRL, either alone, or in
association with other potentially anticancer natural agents, such as
cannabinoid agonists17 and the pineal hormone MLT.18

Acknowledgements
None.

Conflict of interest
The author declares there is no conflict of interest.

References
1. Welsch HWC. Prolactin and murine mammary tumorigenesis: a review. ClinOncol. 1977;3:91–95.
2. Holtkamp W, Nagel GA, Wander HE, et al. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer. 1984;34:323–328.
3. Bhatavedkar JM, Shah NG, Balar DB, et al. Plasma prolactin an indicator of disease progression in advanced breast cancer. Cancer. 1990;65:2028–2032.
4. Vonderhaar BK. Prolactin involvement in breast cancer. Endocrinol Cancer. 1999;6:389–404.
5. Lissoni P, Bucovec R, Malugani F, et al. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines. Anticancer Res. 2000;20:1131–1134.
6. O’Leary KA, Rugowski DE, Sullivan R, et al. Prolactin cooperates with breast cancer. Int J Cancer. 1990;65:2028–2032.
7. Lopez-Ozuna VM, Hachim IH, Hachim MY, et al. Prolactin pro-differentiation pathway in triple negative breast cancer: impact on prognosis and potential therapy. Sci Rep. 2016;6:30934.

Citation: Lissoni P, Messina FRG, Cenay V, et al. Possible influence of prolactin secretion on the survival time in untreated metastatic triple negative breast cancer patients. MOJ Lymphol Phlebol. 2018;2(5):47–49. DOI: 10.15406/mojlp.2018.02.00018
Possible influence of prolactin secretion on the survival time in untreatable metastatic triple negative breast cancer patients

Citation: Lissoni P, Messina FRG, Cenay V, et al. Possible influence of prolactin secretion on the survival time in untreatable metastatic triple negative breast cancer patients. MOJ Lymphol Phlebol. 2018;2(5):47-49. DOI: 10.15406/mojlp.2018.02.00018

1. Kristopher C Carver, Lisa M Arendt, Schuler LA. Complex prolactin crosstalk in breast cancer: new therapeutic implications. Mol Cell Endocrinol. 2009;307:1-7.

2. Hachim IY, Hachim MI, Lopez VM, et al. Prolactin is an independent favorable prognostic marker in human breast cancer. Appl Immunohistochem Mol Morpho. 2016;24:238-245.

3. Chen WY, Ramamoorthy P, Chen N, A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin Cancer Res. 1999;5:3583-3593.

4. Riesco F. Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer. 1970;25:135-140.

5. Lissoni P, Brivio F, Fumagalli L, et al. Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res. 2009;29:1847-1852.

6. Gu L, Li H, Chen L, et al. Prognostic role of lymphocyte-to-monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget. 2016;7:7876-7881.

7. Ali S, Ali S. Prolactin receptor regulates Stat5 tyrosine phosphorylation and nuclear translocation by two separate pathways. J Biol Chem. 1998;273:7709-7716.

8. Hachim IY, Hachim MI, Lopez VM, et al. Prolactin is an independent favorable prognostic marker in human breast cancer. Appl Immunohistochem Mol Morpho. 2016;24:238-245.

9. Chen WY, Ramamoorthy P, Chen N, A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin Cancer Res. 1999;5:3583-3593.

10. Riesco F. Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer. 1970;25:135-140.

11. Lissoni P, Brivio F, Fumagalli L, et al. Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res. 2009;29:1847-1852.

12. Gu L, Li H, Chen L, et al. Prognostic role of lymphocyte-to-monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget. 2016;7:7876-7881.

13. Ali S, Ali S. Prolactin receptor regulates Stat5 tyrosine phosphorylation and nuclear translocation by two separate pathways. J Biol Chem. 1998;273:7709-7716.

14. Kristopher C Carver, Lisa M Arendt, Schuler LA. Complex prolactin crosstalk in breast cancer: new therapeutic implications. Mol Cell Endocrinol. 2009;307:1-7.

15. Jablonska C, Pula B, Zemla A, et al. Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma. J Pineal Res. 2013;54:334-335.

16. Morales P, Blasco-Benito S, Andrades C, et al. Selective non-toxic CB2 cannabinoid quinone with in vitro activity against triple-negative breast cancer. J Med Chem. 2015;58:2256-2264.

17. Grotenehrmen F. Pharmacology of cannabinoids. Neuroendocrinol Lett. 2004;25:14-23.

18. Brzezinsky A. Melatonin in humans. N Engl J Med. 1997;336:186-195.